1 |
Neumann B, Lippmann N, Wendt S, Karlas T, Lübbert C, Werner G, Pfeifer Y, Schuster CF. Recurrent bacteremia with a hypermucoviscous Escherichia coli isolated from a patient with perihilar cholangiocarcinoma: insights from a comprehensive genome-based analysis. Ann Clin Microbiol Antimicrob 2022;21:28. [PMID: 35751078 DOI: 10.1186/s12941-022-00521-7] [Reference Citation Analysis]
|
2 |
Mayo MJ. Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis? Hepatology 2022. [PMID: 35152430 DOI: 10.1002/hep.32405] [Reference Citation Analysis]
|
3 |
Simanenkov V, Maev I, Tkacheva O, Alekseenko S, Andreev D, Bakulina N, Bakulin I, Bordin D, Vlasov T, Vorobyeva N, Grinevich V, Gubonina I, Drobizhev M, Efremov N, Karateev A, Kotovskaya Y, Kravchuk I, Krivoborodov G, Kulchavenya E, Lila A, Maevskaya M, Nekrasova A, Poluektova E, Popkova T, Sablin O, Solovyeva O, Suvorov A, Tarasova G, Trukhan D, Fedotova A. Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians. Terapevticheskii arkhiv. [DOI: 10.26442/00403660.2022.08.201523] [Reference Citation Analysis]
|
4 |
Salas-silva S, López-ramirez J, Barrera-chimal J, Lazzarini-lechuga R, Simoni-nieves A, Souza V, Miranda-labra RU, Masso F, Roma MG, Gutiérrez-ruiz MC, Bucio-ortiz L, Gomez-quiroz LE. Hepatocyte growth factor reverses cholemic nephropathy associated with α-naphthylisothiocyanate-induced cholestasis in mice. Life Sciences 2022;295:120423. [DOI: 10.1016/j.lfs.2022.120423] [Reference Citation Analysis]
|
5 |
Chen L, Zhao X, Wei S, Ma X, Liu H, Li J, Jing M, Wang M, Zhao Y. Mechanism of Paeoniflorin on ANIT-Induced Cholestatic Liver Injury Using Integrated Metabolomics and Network Pharmacology. Front Pharmacol 2021;12:737630. [PMID: 34526905 DOI: 10.3389/fphar.2021.737630] [Reference Citation Analysis]
|